Is there an ETF for CRISPR?

Although there isn't an ETF that solely focuses on CRISPR, several ETFs hold the stocks of companies marketing or developing CRISPR gene-editing therapies.

What ETF holds CRISPR Therapeutics?

Several ETFs own CRISPR Therapeutics. They include the Ark Genomic Revolution ETF, the Global X Genomics & Biotechnology ETF, the iShares Genomics Immunology and Healthcare ETF, and the WisdomTree BioRevolution Fund.

Does CRISPR Therapeutics pay a dividend?

No, CRISPR Therapeutics does not currently pay a dividend.

Is CRISPR Therapeutics a strong buy?

Whether or not to buy shares of CRISPR Therapeutics depends on your investing style. The stock isn't a good fit for risk-averse investors. Aggressive investors, however, could find CRISPR Therapeutics attractive.

What companies are typically included in CRISPR ETFs?

Companies that focus primarily on developing CRISPR therapies are typically included in CRISPR ETFs, such as CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics.

How do CRISPR ETFs differ from investing in individual CRISPR stocks?

The primary difference between investing in CRISPR ETFs and individual CRISPR stocks is convenience. A CRISPR ETF allows investors to buy a basket of CRISPR stocks in one swoop, rather than completing multiple individual transactions. Cost is another key difference. CRISPR ETFs charge fees that investors must pay, while buying individual stocks doesn't come with those fees. On the other hand, if a brokerage charges for each trade, buying CRISPR ETFs may lower those costs compared to buying individual CRISPR stocks.

What CRISPR company did Bill Gates invest in?

Billionaire Bill Gates was part of a group that invested in early funding for Editas Medicine. The charitable organization that he and his ex-wife founded, the Bill & Melinda Gates Foundation, has also funded grants won by CRISPR Therapeutics and Intellia Therapeutics.

Best CRISPR Gene Editing ETFs for 2026 and How to Invest

These exchange-traded funds track companies in this biotech space.

By Keith Speights – Updated May 11, 2026 at 1:45 AM EST | Fact-checked by Frank Bass

+Fool.comon

Key Points

CRISPR ETFs offer diversified exposure to gene-editing stocks, lessening individual stock research.
Investing in CRISPR ETFs involves risks like high volatility and potential clinical failures.
CRISPR ETFs suit aggressive investors, aiming for significant long-term growth from CRISPR advances.

CRISPR ETFs are exchange-traded funds (ETFs) that own the stocks of companies focusing on CRISPR gene editing. By now, many investors have probably heard enough about CRISPR (clustered regularly interspaced short palindromic repeats) to be relatively familiar with the idea.

Gene-editing technology has the potential to change the treatment of many diseases by modifying DNA to correct mutations. CRISPR could even cure diseases in some cases. The ETFs that own the best CRISPR stocks could be big winners for investors over the long run.

Top CRISPR gene-editing ETFs for 2026

Quite a few biotech ETFs are available for investors to buy. The number of CRISPR gene-editing ETFs, however, is more limited. Here are the top five ETFs that focus on CRISPR gene editing.

Loading paragraph...

Data source: ETF websites as of May 8, 2026.
ETF and Ticker	Expense Ratio
ARK Genomic Revolution ETF (NYSEMKT:ARKG)	0.75%
Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)	0.50%
Invesco Dynamic Biotechnology & Genome ETF (NYSEMKT:PBE)	0.58%
iShares Genomics Immunology and Healthcare ETF (NYSEMKT:IDNA)	0.47%
Wisdom Tree BioRevolution Fund (BATS:WDNA)	0.45%

Loading table...

1. ARK Genomic Revolution ETF

NYSEMKT: ARKG

Ark ETF Trust - Ark Genomic Revolution ETF

Today's Change

(-3.90%) $-1.68

Current Price

$41.33

Key Data Points

AUM

$1.3B

Expense Ratio

0.75%

Top Holdings

TEM

7.96%

TXG

7.72%

TWST

7.39%

Loading company_card...

ARK Genomic Revolution ETF (ARKG -3.90%) is one of several ETFs established by Cathie Wood's Ark Invest. It's an actively managed ETF that focuses on companies poised to benefit from incorporating genomics into their operations.

Although the fund isn't limited to CRISPR and genome-editing stocks, there are several in its portfolio. The ETF's largest holding is CRISPR Therapeutics (CRSP -5.31%), which is a pioneer in CRISPR gene editing.

ARK Genomic Revolution ETF also owns shares of other drugmakers with CRISPR therapies in development or on the market, including Beam Therapeutics (BEAM -8.77%), and Intellia Therapeutics (NTLA -7.61%).

Loading paragraph...

2. Global X Genomics & Biotechnology ETF

NASDAQ: GNOM

Global X Funds - Global X Genomics & Biotechnology ETF

Today's Change

(-3.22%) $-1.89

Current Price

$56.65

Key Data Points

AUM

$87M

Dividend Yield

1.15%

Expense Ratio

0.50%

Top Holdings

6.06%

ILMN

4.94%

TWST

4.72%

Loading company_card...

Global X Genomics & Biotechnology ETF (GNOM -3.22%) is run by the South Korean investment firm Mirae Asset Financial Group. This ETF looks for companies that should benefit from advances in genomics, including breakthroughs in gene editing and genomic sequencing.

The Global X Genomics & Biotechnology ETF held about 50 stocks in May 2026. Six of them -- CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics, Vertex Pharmaceuticals (VRTX -2.22%), Editas Medicine (EDIT -1.21%), and Caribou Biosciences (CRBU -0.77%) -- market or are developing CRISPR gene-editing therapies. Two other holdings, Genscript Biotech and Agilent (A +0.72%), offer CRISPR products and services to drug developers and researchers.

3. Invesco Dynamic Biotechnology & Genome ETF

Loading paragraph...

NYSEMKT: PBE

Invesco Exchange-Traded Fund Trust - Invesco Biotechnology & Genome ETF

Today's Change

(-1.98%) $-1.84

Current Price

$91.17

Key Data Points

AUM

$286M

Dividend Yield

1.70%

Expense Ratio

0.58%

Top Holdings

VRTX

4.97%

AMGN

4.83%

RPRX

4.68%

Loading company_card...

The Invesco Dynamic Biotechnology & Genome ETF (GNOM -3.22%) seeks to track an index of 31 U.S. biotechnology and genome companies. Not all of these companies focus on CRISPR or other types of gene editing, but several do. Among this ETF's top 10 holdings, two are connected to gene editing: Regeneron Pharmaceuticals (REGN -0.51%) and Gilead Sciences (GILD -3.72%).

Regeneron is working with Intellia Therapeutics. Gilead teamed up with Sangamo Therapeutics (NASDAQ:SGMO) to develop cancer cell therapies using Sangamo's zinc-finger nuclease (ZFN) gene-editing method, an older technology than CRISPR.

Loading paragraph...

4. iShares Genomics Immunology and Healthcare ETF

NYSEMKT: IDNA

iShares Trust - iShares Genomics Immunology And Healthcare ETF

Today's Change

(-2.75%) $-0.95

Current Price

$33.55

Key Data Points

AUM

$196M

Dividend Yield

0.84%

Expense Ratio

0.47%

Top Holdings

MRNA

5.51%

BAYN.DE

4.73%

TWST

4.62%

Loading company_card...

The iShares Genomics Immunology and Healthcare ETF (IDNA -2.75%) seeks to track an index of companies in developed and emerging markets that focus on genomics, immunology, and bioengineering. It held positions in 52 pharmaceutical and biotech stocks in May 2026.

This ETF's holdings include three previously mentioned stocks with CRISPR gene-editing ties that are owned by the other ETFs on the list: CRISPR Therapeutics, Intellia Therapeutics, and Vertex Pharmaceuticals.

5. WisdomTree BioRevolution Fund

Loading paragraph...

NYSEMKT: WDNA

WisdomTree Trust - WisdomTree BioRevolution Fund

Today's Change

(-3.32%) $-0.70

Current Price

$20.50

Key Data Points

AUM

$2.7M

Dividend Yield

3.76%

Expense Ratio

0.45%

Top Holdings

LLY

3.98%

TWST

3.56%

MRNA

3.44%

Loading company_card...

The WisdomTree BioRevolution Fund (WDNA -3.32%) seeks to track the performance of an index consisting of companies that "will be significantly transformed by advancements in genetics and biotechnology." Like the other ETFs discussed, it doesn't limit itself to only CRISPR or gene-editing stocks.

This fund owns several CRISPR gene-editing stocks that are in the previously mentioned portfolios: Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, Gilead Sciences, Intellia Therapeutics, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals.

Loading paragraph...

How to buy CRISPR ETFs

Follow these steps to buy a CRISPR ETF:

Open your brokerage app: Log in to your brokerage account where you manage your investments. If you don't have one yet, take a look at our favorite brokers and trading platforms to find the right one for you.
Search for the ETF: Enter the ticker or company name into the search bar to bring up the ETF's trading page.
Decide how many shares to buy: Consider your investment goals and how much of your portfolio you want to allocate to this ETF.
Select order type: Choose between a market order to buy at the current price or a limit order to specify the maximum price you're willing to pay.
Submit your order: Confirm the details and submit your buy order.
Review your purchase: Check your portfolio to ensure your order was filled as expected and adjust your investment strategy accordingly.

Loading paragraph...

Benefits and risks of investing in CRISPR gene-editing ETFs

The benefits of investing in CRISPR gene-editing ETFs include:

Significant long-term potential for CRISPR technology.
Diversification across multiple stocks focused on CRISPR gene editing.
Less research is required than selecting individual CRISPR stocks.

However, there are some risks associated with investing in these ETFs as well, including:

High volatility.
Clinical and regulatory failures for multiple CRISPR companies in the portfolio could cause the ETF to underperform.
Relatively high expense fees.

Loading paragraph...

Should you invest in CRISPR gene-editing ETFs?

CRISPR ETFs won't be a good fit for risk-averse investors. If you're seeking income, you'll also want to look for other alternatives, since most of the major CRISPR ETFs don't pay dividends.

However, if you're an aggressive investor, you could find CRISPR ETFs attractive. These funds offer a way to profit from the expanded use of CRISPR therapies without having to pick individual stocks.

Loading paragraph...

FAQ

Investing in CRISPR Gene Editing ETFs: FAQ

Loading faq...

About the Author

Keith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

TMFFishBiz

Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Beam Therapeutics, CRISPR Therapeutics, Gilead Sciences, Intellia Therapeutics, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Best CRISPR Gene Editing ETFs for 2026 and How to Invest

These exchange-traded funds track companies in this biotech space.

Key Points

Top CRISPR gene-editing ETFs for 2026

1. ARK Genomic Revolution ETF

Key Data Points

2. Global X Genomics & Biotechnology ETF

Key Data Points

3. Invesco Dynamic Biotechnology & Genome ETF

Key Data Points

4. iShares Genomics Immunology and Healthcare ETF

Key Data Points

5. WisdomTree BioRevolution Fund

Key Data Points

How to buy CRISPR ETFs

Benefits and risks of investing in CRISPR gene-editing ETFs

Should you invest in CRISPR gene-editing ETFs?

Related investing topics

Best Marijuana Stocks for 2026 and How to Invest

5 Best Psychedelic Stocks for 2026 and How to Invest

6 Best Healthcare Stocks for 2026 and How to Invest

Biotech vs. Pharma: What's the Difference?

FAQ

Investing in CRISPR Gene Editing ETFs: FAQ

Is there an ETF for CRISPR?

Is there an ETF for CRISPR?

What ETF holds CRISPR Therapeutics?

What ETF holds CRISPR Therapeutics?

Does CRISPR Therapeutics pay a dividend?

Does CRISPR Therapeutics pay a dividend?

Is CRISPR Therapeutics a strong buy?

Is CRISPR Therapeutics a strong buy?

What companies are typically included in CRISPR ETFs?

What companies are typically included in CRISPR ETFs?

How do CRISPR ETFs differ from investing in individual CRISPR stocks?

How do CRISPR ETFs differ from investing in individual CRISPR stocks?

What CRISPR company did Bill Gates invest in?

What CRISPR company did Bill Gates invest in?

About the Author

Read Next

Stocks Mentioned

Motley Fool Stock Advisor’s Latest Pick

Premium Investing Services

Top CRISPR gene-editing ETFs for 2026

Key Data Points

5. WisdomTree BioRevolution Fund

How to buy CRISPR ETFs

Benefits and risks of investing in CRISPR gene-editing ETFs

Should you invest in CRISPR gene-editing ETFs?

Best Marijuana Stocks for 2026 and How to Invest

5 Best Psychedelic Stocks for 2026 and How to Invest

6 Best Healthcare Stocks for 2026 and How to Invest

Biotech vs. Pharma: What's the Difference?

Investing in CRISPR Gene Editing ETFs: FAQ

Is there an ETF for CRISPR?

Is there an ETF for CRISPR?

What ETF holds CRISPR Therapeutics?

What ETF holds CRISPR Therapeutics?

Does CRISPR Therapeutics pay a dividend?

Does CRISPR Therapeutics pay a dividend?

Is CRISPR Therapeutics a strong buy?

Is CRISPR Therapeutics a strong buy?

What companies are typically included in CRISPR ETFs?

What companies are typically included in CRISPR ETFs?

How do CRISPR ETFs differ from investing in individual CRISPR stocks?

How do CRISPR ETFs differ from investing in individual CRISPR stocks?

What CRISPR company did Bill Gates invest in?

What CRISPR company did Bill Gates invest in?

Key Data Points

Key Data Points

Key Data Points

Key Data Points

3. Invesco Dynamic Biotechnology & Genome ETF